A recent phase II clinical trial tested erlotinib alone and cabozantinib alone or in combination with erlotinib to treat wild-type EGFR NSCLC patients in a randomized, controlled, open-label, multicenter study finding that progression free survival was improved in the cabozantinib arms. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.